Cargando…
Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement
PURPOSE: To assess the safety and efficacy of a ciliary neurotrophic factor (CNTF) intraocular implant on neuroprotection and neuroenhancement in glaucoma. DESIGN: Open-label, prospective, phase I clinical trial. PARTICIPANTS: A total of 11 participants were diagnosed with primary open-angle glaucom...
Autores principales: | Goldberg, Jeffrey L., Beykin, Gala, Satterfield, Kellie R., Nuñez, Mariana, Lam, Byron L., Albini, Thomas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183667/ https://www.ncbi.nlm.nih.gov/pubmed/37197702 http://dx.doi.org/10.1016/j.xops.2023.100298 |
Ejemplares similares
-
Temporal Alterations of Sphingolipids in Optic Nerves After Indirect Traumatic Optic Neuropathy
por: Chauhan, Muhammad Z., et al.
Publicado: (2022) -
Younger age is associated with greater early neurocognitive decline postcardiopulmonary bypass
por: Anderson, Kelsey, et al.
Publicado: (2020) -
Neuroprotection, Neuroenhancement, and Neuroregeneration of the Retina and Optic Nerve
por: Johnson, Thomas V., et al.
Publicado: (2022) -
Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
por: Lin, Cheng-Wen, et al.
Publicado: (2018) -
Ciliary neurotrophic factor in patients with primary open-angle glaucoma and age-related cataract
por: Shpak, Alexander A., et al.
Publicado: (2017)